News|Videos|November 2, 2023
Trastuzumab Deruxtecan for Patients With HER2+ Metastatic Breast Cancer (mBC)
Author(s)Joseph Gligorov, MD, PhD
Dr Joseph Gligorov highlights the impact of trastuzumab deruxtecan in treating HER2-positive breast cancer due to its impressive results in progression-free survival and overall survival, emphasizing its importance in early treatment, while acknowledging the need to monitor safety issues.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
The CHMP has recommended the approval of sacituzumab govitecan/pembrolizumab for treatment-naive, PD-L1-positive metastatic TNBC in the European Union.
Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA has approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
2
Dr Tarantino on the Evolution of TROP2-Directed ADCs in First-Line TNBC
3
Dr Hurvitz on Updated PFS Data From the SERENA-6 Trial in Breast Cancer
4
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
5